IRAP/EUROPEAN-PIRATES
A webinar on Citizen Focused Disease Prevention, organised by the Institute for Rational Drug Policies (IRAP) in cooperation with the European Pirates, established that harm reduction policies should be used to help people with a wide range of addictions, including smoking.
“We support the concept of harm reduction. Pirates emphasise the need to focus long-term attention on drug use and addictions,” said Mikuláš Peksa, Czech Green MEP. “We are working on a long-term prevention programme of minimising risks at the national level and at the European level. We must also consider how to minimise the negative impact of government drug policies and laws, and this point of view should also be followed by the European Commission.”
The European Commission currently fails to recognise the potential of harm reduction policies even though there is clear public support for them as shown by the recent Town Hall organised by the Commission on Europe's Beating Cancer Plan. Despite harm reduction being perceived by the Town Hall audience as being extremely important, the Commission still refuses to take harm reduction seriously.
According to Jindrich Voboril, Head of IRAP and former long-term National Anti-Drug Coordinator in the Czech Republic: “We have to consider harm reduction not only as a type of social or health service but as a complex approach that should also be incorporated into law and drug policies.”
Advising how to embrace harm reduction into practice: “One part of it is changing the European Commission’s structure. How can we be effective when illicit drugs are solved with one set of criteria, licit drugs with another and problem gambling is left aside altogether? The current situation does not allow effective solution to drug policies and it is hardly cost-effective. The structure of the Directorate General must be changed and the mandate of the EMCDDA (European Monitoring Centre for Drugs and Drug Addictions) must be strengthened. In the context of the ongoing debate on Europe’s Beating Cancer Plan, it’s time that the European Commission begins to take the concept of harm reduction seriously,” concluded Voboril.
“Harm reduction is a broad concept that can complement other approaches, for example when tackling addiction,” said Kasia Kowalczyk from The Global Public Health Network alongside her colleague David Mackintosh. “Harm Reduction has untapped potential across different areas of public health. It works best through a collaborative approach and engages the beneficiaries of public health services or other interventions.”
During the discussion, Hana Horka from the European Commission’s DG SANTE was not enthusiastic about harmonising approaches to addiction. Ms. Horka, despite endorsing harm reduction policies for drug addiction, did not endorse harm reduction policies for tobacco or alcohol, instead advocating for tax increases and prohibitive measures on tobacco products.
Abstinence should not be regarded as the only option for addicts. The goal of harm reduction policies is to keep people alive, help them to make positive changes in their lives and offer them alternatives that cause less harm.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201014005876/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
